


CORRECTION

Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study

Guttorm Raknes, Lars Småbrekke

There are a number of errors in [Table 3](#). The value in column 7 "% points" for the line "LDN x 4+" in the group "All examined medicines" should be -3.3, not 0. Additionally, the p-values in the ninth column "P" are incorrect. Please see the correct [Table 3](#) here.



OPEN ACCESS

Citation: Raknes G, Småbrekke L (2019) Correction: Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS ONE 14(10): e0223545. <https://doi.org/10.1371/journal.pone.0223545>

Published: October 1, 2019

Copyright: © 2019 Raknes, Småbrekke. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 3. The number of users of examined medicines among patients with rheumatoid and seropositive arthritis one year before and after the first dispense of LDN.

| | | Number of users | | | | Difference | | p |
|--|-----------|-----------------|--------|-------|--------|------------|-----------------|-------|
| | | Before | % | After | % | % points | 95% CI | |
| All examined medicines | LDN x 1 | 104 | (99.0) | 100 | (95.2) | -3.8 | (-7.5 to -0.2) | 0.048 |
| | LDN x 2–3 | 70 | (93.3) | 73 | (97.3) | 4.0 | (-1.8 to 9.8) | 0.184 |
| | LDN x 4+ | 170 | (94.4) | 164 | (91.1) | -3.3 | (-7.7 to 1.0) | 0.135 |
| DMARD | LDN x 1 | 70 | (66.7) | 69 | (65.7) | -1.0 | (-9.1 to 7.2) | 0.819 |
| | LDN x 2–3 | 44 | (58.7) | 48 | (64.0) | 5.3 | (-3.6 to 14.3) | 0.252 |
| | LDN x 4+ | 94 | (52.2) | 82 | (45.6) | -6.7 | (-12.3 to -1.0) | 0.025 |
| NSAIDs | LDN x 1 | 73 | (69.5) | 63 | (60.0) | -9.5 | (-18.1 to -1.0) | 0.035 |
| | LDN x 2–3 | 53 | (70.7) | 47 | (62.7) | -8.0 | (-18.3 to 2.3) | 0.138 |
| | LDN x 4+ | 121 | (67.2) | 114 | (63.3) | -3.9 | (-10.5 to 2.7) | 0.251 |
| Analgesics | LDN x 1 | 79 | (75.2) | 80 | (76.2) | 1.0 | (-5.2 to 7.1) | 0.764 |
| | LDN x 2–3 | 55 | (73.3) | 58 | (77.3) | 4.0 | (-7.4 to 15.4) | 0.493 |
| | LDN x 4+ | 115 | (63.9) | 107 | (59.4) | -4.4 | (-10.4 to 1.5) | 0.146 |
| Corticosteroids | LDN x 1 | 53 | (50.5) | 53 | (50.5) | 0.0 | (-9.1 to 9.1) | 1.000 |
| | LDN x 2–3 | 25 | (33.3) | 25 | (33.3) | 0.0 | (-11.1 to 11.1) | 1.000 |
| | LDN x 4+ | 62 | (34.4) | 54 | (30.0) | -4.4 | (-10.6 to 1.7) | 0.159 |
| TNF-α antagonists | LDN x 1 | 15 | (14.3) | 12 | (11.4) | -2.9 | (-7.8 to 2.1) | 0.259 |
| | LDN x 2–3 | 9 | (12.0) | 11 | (14.7) | 2.7 | (-2.5 to 7.9) | 0.321 |
| | LDN x 4+ | 22 | (12.2) | 17 | (9.4) | -2.8 | (-5.2 to -0.4) | 0.027 |
| Other DMARDs | LDN x 1 | 42 | (40.0) | 39 | (37.1) | -2.9 | (-10.5 to 4.8) | 0.468 |
| | LDN x 2–3 | 29 | (38.7) | 31 | (41.3) | 2.7 | (-5.6 to 10.9) | 0.529 |
| | LDN x 4+ | 57 | (31.7) | 45 | (25.0) | -6.7 | (-10.3 to -3.0) | 0.001 |
| Opioids | LDN x 1 | 54 | (51.4) | 55 | (52.4) | 1.0 | (-6.7 to 8.7) | 0.809 |
| | LDN x 2–3 | 42 | (56.0) | 39 | (52.0) | -4.0 | (-15.4 to 7.4) | 0.493 |
| | LDN x 4+ | 77 | (42.8) | 57 | (31.7) | -11.1 | (-19.0 to -3.3) | 0.007 |
| Other analgesics | LDN x 1 | 60 | (57.1) | 64 | (61.0) | 3.8 | (-2.1 to 9.7) | 0.209 |
| | LDN x 2–3 | 36 | (48.0) | 43 | (57.3) | 9.3 | (-1.2 to 19.9) | 0.094 |
| | LDN x 4+ | 88 | (48.9) | 85 | (47.2) | -1.7 | (-7.1 to 3.8) | 0.549 |

LDN, low dose naltrexone. DMARD, disease-modifying antirheumatic drug. NSAID, a non-steroid anti-inflammatory drug. Three groups based on number of LDN dispenses: LDN $\times 1$ ($N = 105$) collected LDN once, LDN $\times 2-3$ ($N = 75$) two or three times and LDN $\times 4+$ ($N = 180$) four or more times. Other DMARDs include methotrexate, antimalarials, aminosaliclates and leflunomide. DMARDs is the sum of TNF- α antagonists, systemic corticosteroids and other DMARDs. Other analgesics include paracetamol/acetaminophen and other non-opioid analgesics.

<https://doi.org/10.1371/journal.pone.0223545.t001>

There are a number of errors in [S2 Table](#). The p-values in the ninth column “P” are incorrect. Please view the correct [S2 Table](#) below.

Supporting information

S2 Table. The number of users of medicines classified as Other DMARDs among patients with rheumatoid and seropositive arthritis one year before and after the first dispense of LDN.

(PDF)

Reference

1. Raknes G, Småbrekke L (2019) Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS ONE 14(2): e0212460. <https://doi.org/10.1371/journal.pone.0212460> PMID: 30763385